Memora Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI care platform automating chronic disease patient communication via SMS for health systems; extends care team capacity across oncology, cardiology, and behavioral health.
About
Memora Health is a San Francisco-based care enablement company that provides health systems with an AI platform to automate patient communication, care navigation, and chronic disease management between clinical visits. The platform uses conversational AI delivered via SMS to check in with patients, answer frequently asked questions, capture symptom reports, and escalate concerning findings to clinical staff — extending care team capacity without adding headcount. Memora targets chronic condition management programs including oncology, cardiovascular care, behavioral health, and pregnancy, where consistent patient monitoring between visits improves outcomes and reduces preventable hospitalizations. The platform integrates with EHR systems and enables care coordinators to manage larger patient panels by automating the routine communication that consumed their time. Founded in 2017, Memora raised over $80M from investors including General Catalyst, Andreessen Horowitz, and Kaiser Permanente Ventures. It competes with Luma Health and Welkin Health in the patient engagement and care management platform market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.